🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

18,91 USD

Máx. histórico

48,47

1806 días

Caída desde máximo

-60,99%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+5,94%

Cierre anterior

17,85

Rango de hoy

18,05 – 18,98

Volumen hoy

1.935.563

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,63%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 23 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
15/03/2019 11,52 11,98 11,52 11,67 +2,10% 3,99% 178.000
14/03/2019 12,28 12,49 11,43 11,43 -6,54% 8,63% 114.000
13/03/2019 12,60 12,70 12,18 12,23 -1,53% 4,13% 285.800
12/03/2019 12,23 12,54 12,02 12,42 +2,39% 4,25% 197.400
11/03/2019 11,78 12,45 11,37 12,13 +3,85% 9,21% 128.100
08/03/2019 11,66 11,79 11,37 11,68 +0,09% 3,64% 42.300
07/03/2019 11,16 11,96 10,61 11,67 +4,38% 12,10% 66.100
06/03/2019 11,99 12,39 10,91 11,18 -6,99% 12,35% 103.000
05/03/2019 12,04 12,44 11,84 12,02 +0,17% 4,98% 79.400
04/03/2019 12,01 12,25 11,54 12,00 +0,33% 5,91% 52.100
01/03/2019 11,85 12,35 11,58 11,96 +1,44% 6,50% 111.300
28/02/2019 11,55 12,00 11,08 11,79 +2,17% 7,97% 133.000
27/02/2019 11,63 12,08 11,42 11,54 -1,03% 5,67% 143.900
26/02/2019 11,74 12,16 11,55 11,66 -0,85% 5,20% 160.000
25/02/2019 11,88 12,18 11,70 11,76 +0,94% 4,04% 159.600
22/02/2019 12,00 12,01 11,60 11,65 -2,84% 3,42% 149.500
21/02/2019 11,57 12,04 11,33 11,99 +3,36% 6,14% 35.600
20/02/2019 11,21 11,70 11,21 11,60 +3,48% 4,37% 35.600
19/02/2019 11,79 12,00 11,15 11,21 -5,72% 7,21% 58.800
15/02/2019 10,83 11,98 10,39 11,89 +10,60% 14,68% 95.800
14/02/2019 10,99 11,75 10,66 10,75 -3,67% 9,92% 70.400
13/02/2019 10,51 11,26 10,43 11,16 +7,20% 7,90% 60.700
12/02/2019 10,56 10,84 10,26 10,41 -0,29% 5,49% 50.000
11/02/2019 10,93 10,93 10,31 10,44 -3,42% 5,67% 32.600
08/02/2019 10,06 10,99 10,06 10,81 +6,82% 9,24% 85.600
07/02/2019 10,04 10,17 9,62 10,12 -0,20% 5,48% 36.600
06/02/2019 10,03 10,29 9,93 10,14 +0,60% 3,59% 36.200
05/02/2019 9,85 10,21 9,75 10,08 +3,07% 4,67% 35.500
04/02/2019 10,43 10,43 9,67 9,78 -6,14% 7,29% 62.900
01/02/2019 10,14 10,52 9,95 10,42 +2,46% 5,62% 79.500